Anbio Biotechnology Class A (NNNN) Key Metrics
NNNN valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $137.4M
- Enterprise value
- $256.3M
- P/E (TTM)
- 20.9
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 15.9
- Price / book
- 8.9
- EV / EBITDA
- 44.4
- Dividend yield
- —
- Beta
- —
NNNN key metrics, 2021–2025
Fiscal year ended December 31, 2025 · U.S. dollarsNNNN returns How much profit the business earns on the capital it uses.
NNNN per-share figures Results divided by the shares outstanding at year-end.
NNNN financial health Debt, liquidity and how easily interest is covered.
NNNN efficiency & capital use Working capital cycle and where the cash goes.
NNNN valuation history
NNNN returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
NNNN debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
NNNN price vs earnings per share
NNNN key metrics
2021–2025| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Valuation | |||||
| Market capitalization | $1.32B | — | — | — | — |
| Enterprise value | $1.31B | — | — | — | — |
| P/E ratio | 206.1 | — | — | — | — |
| Price / sales | 152.6 | — | — | — | — |
| Price / book | 43.8 | — | — | — | — |
| EV / sales | 151.3 | — | — | — | — |
| EV / EBITDA | 226.8 | — | — | — | — |
| Earnings yield | 0.5% | — | — | — | — |
| Free cash flow yield | −0.5% | — | — | — | — |
| Share price at fiscal year-end | $30.07 | — | — | — | — |
| Per share | |||||
| Revenue per share | $0.20 | $0.19 | $0.04 | $0.16 | $0.04 |
| Earnings per share | $0.15 | $0.06 | $0.01 | $0.07 | $0.03 |
| Operating cash flow per share | −$0.15 | $0.05 | $0.00 | $0.03 | $0.04 |
| Free cash flow per share | −$0.15 | $0.05 | $0.00 | $0.03 | $0.04 |
| Cash per share | $0.27 | $0.28 | $0.05 | $0.06 | $0.04 |
| Book value per share | $0.69 | $0.41 | $0.08 | $0.09 | $0.03 |
| Tangible book value per share | $0.69 | $0.41 | $0.08 | $0.09 | $0.03 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares outstanding | 43.9M | 42.3M | 187.8M | 143.9M | 100.0M |
| Change in shares outstanding | +3.8% | −77.5% | +30.5% | +43.9% | — |
| Returns & profitability | |||||
| Return on equity (ROE) | 27.0% | 14.8% | 16.5% | 132.7% | 100.0% |
| Return on invested capital (ROIC) | 38.5% | 29.9% | 34.4% | 721.6% | — |
| Return on assets (ROA) | 26.0% | 13.7% | 15.1% | 106.1% | 51.6% |
| Return on tangible assets | 21.2% | 12.5% | 14.3% | 71.7% | 51.6% |
| Free cash flow margin | −77.9% | 25.4% | 13.4% | 18.9% | 94.4% |
| Income quality (OCF / net income) | −1.05 | 0.88 | 0.40 | 0.44 | 1.65 |
| Financial health | |||||
| Cash & short-term investments | $11.9M | $11.8M | $9.7M | $8.7M | $4.2M |
| Net debt | −$11.9M | −$11.8M | −$9.7M | −$8.7M | −$4.2M |
| Net debt / EBITDA | −2.06 | −5.89 | −4.28 | −0.86 | −1.65 |
| Current ratio | 344.31 | 10.71 | 15.86 | 9.88 | 2.07 |
| Quick ratio | 344.31 | 10.71 | 15.86 | 9.63 | 2.07 |
| Working capital | $30.2M | $16.8M | $14.8M | $12.5M | $2.5M |
| Invested capital | $18.3M | $5.4M | $5.1M | $3.9M | −$1.6M |
| Tangible asset value | $30.2M | $17.2M | $14.8M | $12.5M | $2.5M |
| Net current asset value | $30.2M | $16.8M | $14.8M | $12.5M | $2.5M |
| Graham number | $1.50 | $0.72 | $0.15 | $0.37 | $0.12 |
| Graham net-net per share | $0.33 | $0.26 | $0.05 | $0.05 | $0.02 |
| Capital allocation | |||||
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Capex / operating cash flow | — | 0.0% | 0.0% | 0.0% | 0.0% |
| Capex / depreciation | — | — | 0.00 | 0.00 | — |
| R&D / revenue | 2.3% | 5.5% | 2.0% | 0.8% | — |
| SG&A / revenue | 18.2% | 42.0% | 18.9% | 9.2% | 1.9% |
| Efficiency | |||||
| Days sales outstanding | 99.7 | 65.8 | 51.3 | 5.6 | 59.1 |
| Days of inventory on hand | — | — | — | 5.9 | — |
| Days payables outstanding | 268.7 | 194.6 | 121.7 | 54.8 | 365.7 |
| Cash conversion cycle (days) | -169.1 | -128.8 | -51.1 | -43.3 | -306.5 |
| Receivables turnover | 3.66 | 5.55 | 7.11 | 65.30 | 6.17 |
| Payables turnover | 1.36 | 1.88 | 3.00 | 6.66 | 1.00 |
| Inventory turnover | — | — | — | 62.06 | — |
| Asset turnover | 0.35 | 0.47 | 0.45 | 2.49 | 0.90 |
| Average receivables | $2.4M | $1.5M | $944,270 | $360,540 | $717,500 |
| Average payables | $812,628 | $1.2M | $1.1M | $1.6M | $1.9M |
| Average inventory | — | — | $176,936 | $176,936 | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from NNNN's annual financial statements (latest annual report filed April 7, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
NNNN valuation and financial ratios
At the end of fiscal 2025 (December 31, 2025), Anbio Biotechnology traded at 206.1 times earnings. Based on the latest twelve months, the trailing P/E is 20.9. Anbio Biotechnology earned a return on equity of 27.0% and a return on invested capital of 38.5% in fiscal 2025. The share count fell 56.1% from 100.0M to 43.9M over 4 years.
See the NNNN income statement, the NNNN chart for price history, or the NNNN stock overview for the latest quote and news.
NNNN key metrics FAQ
What is Anbio Biotechnology's P/E ratio?
Anbio Biotechnology's trailing P/E ratio is 20.9 based on the last twelve months of earnings (as of October 18, 2026). At the end of fiscal 2025 it was 206.1.
What is Anbio Biotechnology's EV/EBITDA?
Anbio Biotechnology's enterprise value was 226.8 times EBITDA at the end of fiscal 2025 (enterprise value $1.3 billion, EBITDA $5.8 million); the current EV/EBITDA is 44.4.
What is Anbio Biotechnology's return on equity?
Anbio Biotechnology's return on equity (ROE) was 27.0% in fiscal 2025: net income of $6.4 million on average shareholders' equity of $23.7 million.
What is Anbio Biotechnology's ROIC?
Anbio Biotechnology's return on invested capital was 38.5% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
What is Anbio Biotechnology's free cash flow yield?
Anbio Biotechnology generated -$6.7 million of free cash flow in fiscal 2025, a free cash flow yield of −0.5% on its market value at year-end ($1.3 billion).
What is Anbio Biotechnology's current ratio?
Anbio Biotechnology's current ratio was 344.31 at the end of fiscal 2025: current assets were 344.31 times current liabilities.